FDA Clears Lilly’s Oral Obesity Drug Foundayo for U.S. Market
The U.S. Food and Drug Administration has approved Eli Lilly’s oral weight-loss medication orforglipron, to be marketed as Foundayo. The once-daily pill, designed to replicate the appetite-suppressing action of GLP-1 hormones, will begin shipping April 6 via LillyDirect at $149 per month for the lowest dose for self-pay customers and will soon be a…